

Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-20 (Cancelled).

21. (Previously Presented) A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising
- administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,
 - in an amount that
 - (i) is effective to treat the papules and pustules of rosacea;
 - (ii) is 10-80% of a 50 mg dose of doxycycline; and
 - (iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.
22. (Previously Presented) The method according to Claim 21, wherein said doxycycline is doxycycline monohydrate.
23. (Previously Presented) The method according to Claim 22, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.
24. (Previously Presented) The method according to Claim 23, wherein said doxycycline monohydrate is administered by sustained release.
25. (Previously Presented) A method according to Claim 24, wherein said doxycycline monohydrate is administered once a day.
26. (Previously Presented) The method according to Claim 22, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

27. (Previously Presented) The method according to Claim 21, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 µg/ml.

28. (Previously Presented) A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof,
in an amount that
(i) is effective to treat the papules and pustules of rosacea;
(ii) is 40-80% of a 50 mg dose of doxycycline; and
(iii) results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

29. (Previously Presented) The method according to Claim 28, wherein said doxycycline is doxycycline monohydrate.

30. (Previously Presented) The method according to Claim 29, wherein said doxycycline monohydrate is administered in an amount of 40 milligrams.

31. (Previously Presented) The method according to Claim 30, wherein said doxycycline monohydrate is administered by sustained release.

32. (Previously Presented) A method according to Claim 31, wherein said doxycycline monohydrate is administered once a day.

33. (Previously Presented) The method according to Claim 29, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

34. (Previously Presented) The method according to Claim 28, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 µg/ml.

35. (Previously Presented) A method for treating papules and pustules of rosacea in a human in need thereof, the method comprising
administering orally to said human doxycycline, or a pharmaceutically acceptable salt thereof, in an amount of 40mg per day, wherein the amount results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

36. (Previously Presented) The method according to Claim 35, wherein said doxycycline is doxycycline monohydrate.

37. (Previously Presented) The method according to Claim 36, wherein said doxycycline monohydrate is administered by sustained release.

38. (Previously Presented) A method according to Claim 37, wherein said doxycycline monohydrate is administered once a day.

39. (Previously Presented) The method according to Claim 36, wherein said doxycycline monohydrate is administered in a dose of 20 mg twice a day.

40. (Previously Presented) The method according to Claim 35, wherein said doxycycline, or a pharmaceutically acceptable salt thereof, is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 µg/ml.

REMARKS

Claims 1-20 were previously cancelled. Claims 21-40 were previously added. Thus, Claims 21-40 are pending.

Substance of Interview

Applicant wishes to thank Examiner Susan Tran and Supervisory Patent Examiner Robert Wax for taking the time to discuss the instant application and for their courtesy during a personal interview with Ms. Cécile Cousin, Dr. Vasant Manna, Dr. Irving N. Feit and the undersigned on February 7, 2013. Dr. Manna stated to the examiners that he is a Medical Doctor with expertise in dermatology.

The Claimed Invention

During the interview applicant's representatives explained that the claimed invention is a method for treating papules and pustules of rosacea by oral administration of doxycycline (or a salt thereof). Papules and pustules occur on skin in facial rosacea. The doxycycline dose is expressed differently in each independent claim, i.e., 10-80% of a 50 mg, 40-80% of a 50 mg dose, and a 40 mg. The claims recite that all these doses result in no reduction of skin microflora during a six-month treatment. Applicant's representative emphasized that the treatment of papules and pustules of rosacea with such a dose was major development in the treatment of this condition, and was unknown in the prior art.

Obviousness Rejections under 35 U.S.C. §103(a) in View of Perricone and Pflugfelder

In the Final Office Action, the examiner maintained the obviousness rejections, under 35 U.S.C. §103(a), of Claims 21, 23, 25-28, 30, 32-35 and 38-40 over US 6,365,623 (hereinafter "*Perricone*") in view of US 6,455,583 (hereinafter "*Pflugfelder*"); of Claims 24, 25, 31, 32, 37 and 38 over *Perricone* in view of *Pflugfelder* and US 5,300,304; and of Claims

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.